55th Annual Meeting of the European Association for the Study of Diabetes, Barcelona Risk of microvascular complications over 30 years in latent autoimmune diabetes of adults compared with type 2 diabetes
E. Maddaloni, R.L. Coleman, O.F. Agbaje, R. Buzzetti, R.R. Holman
Diabetologia 2019;62:(Supp 1):S115 [Abstract]
55th Annual Meeting of the European Association for the Study of Diabetes, Barcelona Predicting risk for new-onset type 2 diabetes in Chinese people with coronary heart disease and impaired glucose tolerance
S. Xu, C. Scott, R.L. Coleman, J. Tuomilehto, R.R. Holman
Diabetologia 2019;62:(Supp 1):S150 [Abstract]
55th Annual Meeting of the European Association for the Study of Diabetes, Barcelona Estimating cardiovascular risk and all-cause mortality in individuals with type 2 diabetes using the UKPDS Outcomes Model R.L. Coleman, A.M. Gray, D.K. McGuire, R.R. Holman
Diabetologia 2019;62:(Supp 1):S152 [Abstract]
2018
54th Annual Meeting of the European Association for the Study of Diabetes, Berlin Risk of cardiovascular disease in individuals with latent autoimmune diabetes of adults: results from the UKPDS
E. Maddaloni, R.L. Coleman, P. Pozzilli, R.R. Holman
Diabetelogia 2018;61:(Suppl 1):S574-5 [Abstract]
American Diabetes Association (ADA) Conference, Orlando Regional Variations in Case Fatality following a Major Coronary or Cerebrovascular Event in People with Type 2 Diabetes-Evidence from the ADVANCE Trial and TECOS Trial
PHILIP M. CLARKE, XINYANG HUA, JOHN CHALMERS, MARK WOODWARD, ESQ., RUTH L. COLEMAN, JENNIFER B. GREEN, DARREN K. MCGUIRE, RURY R. HOLMAN
Diabetes 2018;67:(Suppl 1):1299-P [Abstract]
2017
Diabetes UK Annual Professional Conference, Manchester Are the cardiovascular risk reductions seen with empagliflozin in the EMPA-REG OUTCOME trial explained by conventional cardiovascular risk factors? RL Coleman, A Gray, UC Broedl, D Fitchett, JT George, HJ Woerle, B Zinman and RR Holman
Diabetic Medicine 2017;34 (Suppl 1):5 - 35 [Abstract]
Diabetes UK Annual Professional Conference, Manchester Estimating the potential incremental benefits on Type 2 diabetes complications rates of targeting successively lower LDL-cholesterol levels
SA Mostafa, RL Coleman, OF Agbaje, A Gray, RR Holman and MA Bethel
Diabetic Medicine 2017;34 (Suppl 1):36-194 [Abstract]
53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon Predicting post one-year durability of glucose-lowering monotherapies in patients with new-onset type 2 diabetes
O.F. Agbaje, R.L. Coleman, A.T. Hattersley, E.Z. Pearson, R.R. Holman
Diabetelogia 2017;60:(Suppl 1):S300 [Abstract]
53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon Risk of anaemia with long-term metformin use in a community setting
L.A. Donnelly, K. Gardner, R.L. Coleman, N. Sattar, A.T. Hattersley, R.R. Holman, E.R. Pearson
Diabetelogia 2017;60:(Suppl 1):S139 [Abstract]
53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon Are the cardiovascular risk reductions seen with empagliflozin in the EMPA-REG OUTCOME trial explained by conventional cardiovascular risk factors? R.L. Coleman, A.M. Gray, U.C. Broedl, D. Fitchett, J.T. George, H.-J. Woerle, B. Zinman, R.R. Holman
Diabetelogia 2017;60:(Suppl 1):S522 [Abstract]
53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon Modelling incremental benefits on macro- and micro-vascular complications rates when targeting lower systolic blood pressure levels in type 2 diabetes
S.A. Mostafa, R.L. Coleman, O.F. Agbaje, A. Gray, R.R. Holman, M.A. Bethel
Diabetelogia 2017;60:(Suppl 1):S525 [Abstract]
Association of British Clinical Diabetologists (ABCD) Autumn Meeting 2016, Brighton Estimating the potential risk reduction of Type 2 diabetes mellitus (T2DM) complications if systolic blood pressure (SBP) targets were to be lowered
S Mostafa, RL Coleman, OF Agbaje, A Gray, RR Holman, MA Bethel
The British Journal of Diabetes 2017;17:1:42 [Abstract]
2016
52nd Annual Meeting of the European Association for the Study of Diabetes, Munich Estimated 10-year benefit for diabetes complication rates by 1% HbA1c decrements in people with type 2 diabetes and cardiovascular disease
S.A. Mostafa, R.R. Holman, R.L. Coleman, O. Agbaje, M.A. Bethel
Diabetologia 2016;59:Suppl 1:S543 [Abstract]
2012
American Diabetes Association (ADA) Conference, Philadelphia Updated UKPDS Risk Engine that Estimates Primary and Secondary Cardiovascular Disease Risk in People With Recently-Diagnosed or Established Type 2 Diabetes Coleman RL, Stevens RJ, Holman RR
Diabetes 2012;61:Supp 1:A103 [Abstract]
2008
44th Annual Meeting of the European Association for the Study of Diabetes, Rome Performance of the UKPDS Risk Engine and the Framingham risk equations in estimating cardiovascular disease in the EPIC-Norfolk cohort
Simmons RK, Coleman RL, Price HC, Holman RR, Khaw KT, Wareham NJ, Griffin SJ
Diabetologia 2008;51:Suppl 1:S549 [Abstract]
2007
67th Scientific Session of the American Diabetes Association, Chicago The Oxford Risk Engine: A Cardiovascular Risk Calculator for Individuals with or without Type 2 diabetes Coleman RL, Stevens RJ, Holman RR
Diabetes 2007;56:Suppl 1:A170 [Abstract]
The Diabetes UK Annual Professional Conference, Glasgow Estimating cardiovascular disease risk for individuals with Type 2 diabetes: the new UKPDS Risk Engine Coleman RL, Stevens RJ, Holman RR
Diabetic Medicine 2007;24:Suppl 1:56 [Abstract]
Diabetes UK Annual Professional Conference, Glasgow Framingham Equations Underestimate Cardiovascular Risk Compared with the UKPDS Risk Engine in People with Type 2 Diabetes.
Price HC, Cull CA, Coleman RL, Stevens RJ and Holman RR
Diabetic Medicine 2007;24:suppl 1:55 [Abstract]
43rd Annual Meeting of the European Association for the Study of Diabetes, Amsterdam Are measures of adiposity associated independently with incident cardiovascular disease in individuals with newly diagnosed type 2 diabetes? Coleman RL, Holman RR
Diabetologia 2007;50:Suppl 1:S502 [Abstract]
2006
Diabetes UK Annual Professional Conference, Birmingham Estimating risk of clinically evident neuropathy in type 2 diabetes: a UKPDS risk equation Coleman RL, Stevens RJ, Holman RR
Diabetic Medicine 2006;23:Suppl. 2:51
66th Scientific Session of the American Diabetes Association, Washington Estimating Risk of Clinically Evident Retinopathy in Type 2 Diabetes. Coleman RL, Stevens RJ, Aldington SJ, Holman RR
Diabetes 2006;55:Suppl 1:A53
2005
65th Scientific Sessions of the American Diabetes Association, San Diego A Cardiovascular Risk Calculator for Type 2 Diabetes Coleman RL, Stevens RJ, Matthews DR, Holman RR
Diabetes 2005;54:Suppl 1:A172
41st Annual Meeting of the European Association for the Study of Diabetes, Athens Incident nephropathy in type 2 diabetes: a UKPDS Risk Equation Coleman RL, Stevens RJ, Holman RR
Diabetologia 2005;48:Suppl 1:A32
2004
40th Annual Meeting of the European Association for the Study of Diabetes, Munich Evaluating SCORE and Framingham fatal coronary heart disease risk equations using UKPDS data Coleman RL, Stevens RJ, Holman RR
Diabetologia 2004;47:Suppl 1:A42
40th Annual Meeting of the European Association for the Study of Diabetes, Munich Could non-HDL cholesterol replace total/HDL cholesterol ratio to estimate coronary heart disease risk in the UKPDS risk engine?
Stevens RJ, Coleman RL, Shine BL, Holman RR
Diabetologia 2004;47:Suppl 1:A61 [Abstract]
2002
62nd Scientific Sessions of the American Diabetes Association, San Francisco Forecasting Coronary Case Fatality in Type 2 Diabetes: A UKPDS Risk Engine Equation
Stevens RJ, Coleman RL, Adler AI, Stratton IM, Holman RR
Diabetes 2002;51:Suppl 2:A172
Diabetes Trials Unit, OCDEM, Churchill Hospital, Old Road, Headington, Oxford, OX3 7LJ
Tel: +44 (0)1865 857240 Email: dtu@dtu.ox.ac.uk
